148 related articles for article (PubMed ID: 28272989)
1. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.
Meleshko AN; Petrovskaya NA; Savelyeva N; Vashkevich KP; Doronina SN; Sachivko NV
Hum Vaccin Immunother; 2017 Jun; 13(6):1-6. PubMed ID: 28272989
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
4. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
[TBL] [Abstract][Full Text] [Related]
5. Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study.
Meleshko A; Piatrouskaya N; Vashkevich K; Lutskovich D; Wang C; Dormeshkin D; Savelyeva N; Katsin M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884359
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.
Thomas SK; Cha SC; Smith DL; Kim KH; Parshottam SR; Rao S; Popescu M; Lee VY; Neelapu SS; Kwak LW
BMC Cancer; 2018 Feb; 18(1):187. PubMed ID: 29439670
[TBL] [Abstract][Full Text] [Related]
7. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
[TBL] [Abstract][Full Text] [Related]
8. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
[TBL] [Abstract][Full Text] [Related]
11. An enhanced immune response against G250, induced by a heterologous DNA prime‑protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant.
Sun Z; Liu B; Ruan X; Liu Q
Mol Med Rep; 2014 Nov; 10(5):2657-62. PubMed ID: 25190325
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH
Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effect of swine CCL20 chemokine in DNA vaccination against CSFV.
Tarradas J; Álvarez B; Fraile L; Rosell R; Muñoz M; Galindo-Cardiel I; Domingo M; Dominguez J; Ezquerra A; Sobrino F; Ganges L
Vet Immunol Immunopathol; 2011 Aug; 142(3-4):243-51. PubMed ID: 21684019
[TBL] [Abstract][Full Text] [Related]
14. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
[TBL] [Abstract][Full Text] [Related]
15. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
McCann KJ; Godeseth R; Chudley L; Mander A; Di Genova G; Lloyd-Evans P; Kerr JP; Malykh VB; Jenner MW; Orchard KH; Stevenson FK; Ottensmeier CH
Cancer Immunol Immunother; 2015 Aug; 64(8):1021-32. PubMed ID: 25982371
[TBL] [Abstract][Full Text] [Related]
16. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
17. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of new DNA vaccine with polyethylenimine induces cellular immune response and tumor regression in neuroblastoma mouse model.
Stegantseva MV; Shinkevich VA; Tumar EM; Meleshko AN
Exp Oncol; 2020 Jun; 42(2):120-125. PubMed ID: 32602294
[TBL] [Abstract][Full Text] [Related]
19. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
Koumarianou A; Kountourakis P; Economopoulos T
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):230-2. PubMed ID: 18406604
[TBL] [Abstract][Full Text] [Related]
20. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.
Jin X; Morgan C; Yu X; DeRosa S; Tomaras GD; Montefiori DC; Kublin J; Corey L; Keefer MC;
Vaccine; 2015 May; 33(20):2347-53. PubMed ID: 25820067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
